XEN1101 / Xenon 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   3 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
XEN1101 / Xenon
X-TOLE2, NCT05614063: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Recruiting
3
360
Europe, Canada, US, RoW
XEN1101, Placebo
Xenon Pharmaceuticals Inc., Worldwide Clinical Trials
Focal Onset Seizures
04/25
06/25
X-ACKT, NCT05667142: A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Recruiting
3
160
Europe, Canada, US, RoW
XEN1101, Placebo
Xenon Pharmaceuticals Inc., Worldwide Clinical Trials
Primary Generalized Tonic-Clonic Seizures
06/25
10/25
NCT05716100: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Recruiting
3
360
Europe, US, RoW
XEN1101, Placebo
Xenon Pharmaceuticals Inc., Worldwide Clinical Trials
Focal Onset Seizures
08/25
12/25
X-TOLE4, NCT05718817: An Open-label Study of XEN1101 in Epilepsy

Enrolling by invitation
3
880
Europe, Canada, US
XEN1101
Xenon Pharmaceuticals Inc., Worldwide Clinical Trials
Focal Epilepsy, Tonic-Clonic Seizures
07/28
09/28
2018-003221-29: A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilepsy, with an Open-label Extension.

Not yet recruiting
2
300
Europe, RoW
XEN1101, XEN1101, Capsule
Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals Inc, Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals Inc
Adult focal (partial onset) epilepsy, Adult focal epilepsy, Diseases [C] - Nervous System Diseases [C10]
 
 
X-TOLE, NCT03796962: A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Active, not recruiting
2
325
Europe, Canada, US, RoW
XEN1101
Xenon Pharmaceuticals Inc., Novotech Health Holdings Pte. Ltd.
Focal Epilepsy
09/21
10/28
X-NOVA, NCT05376150: A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Completed
2
168
US
XEN1101 10 mg, XEN1101 20 mg, Placebo
Xenon Pharmaceuticals Inc.
Major Depressive Disorder
09/23
10/23
NCT04827901: XEN1101 for Major Depressive Disorder

Recruiting
2
60
US
XEN1101, Placebo
James Murrough, Baylor College of Medicine, National Institute of Mental Health (NIMH)
Major Depressive Disorder
11/24
12/24

Download Options